Company: LBRX
Filing Date: 2025-08-22
Form Type: S-1
Source: 0001193125-25-186467
Chunk: 19

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-08-22
Form: S-1
Chunk 19
---
 to incur significant losses for

12

the foreseeable future, and we expect these losses to increase as we continue our development of our product candidate. We anticipate that our expenses will increase substantially if, and as, we:

| • |     | conduct further clinical trials for LB-102 in patients with                                                                                                                
 schizophrenia, initiate clinical development of LB-102 in bipolar depression and other neuropsychiatric indications, and advance our preclinical programs into the clinic; |

| • |     | identify additional product candidates and acquire rights from third parties to those product candidates through       
 licenses or other acquisitions, and conduct development activities, including preclinical studies and clinical trials; |

| • |     | procure the manufacturing of preclinical, clinical, and commercial supply of our current and future product 
 candidates;                                                                                                 |

| • |     | seek regulatory approvals for our product candidate or any future product candidates; |

| • |     | commercialize our current product candidate or any future product candidates, if approved; |

| • |     | take steps toward our goal of being an integrated biopharmaceutical company capable of supporting commercial 
 activities, including establishing sales, marketing and distribution infrastructure;                         |

| • |     | attract, hire, and retain qualified clinical, scientific, operations, and management personnel; |

| • |     | add and maintain operational, financial, and information management systems; |

| • |     | protect, maintain, enforce, and defend our rights in our intellectual property portfolio; |

| • |     | defend against third-party interference, infringement, and other intellectual property claims, if any; |

| • |     | address any competing therapies and market developments; |

| • |     | experience any delays in our preclinical studies or clinical trials and regulatory approval for our product                                               
 candidate due to macroeconomic conditions, geopolitical conflicts, or other global events, including any health epidemics and their residual effects; and |

| • |     | incur additional costs, including legal, accounting, and other expenses, associated with operating as a public 
 company following the completion of this offering.                                                             |

We have no product candidates approved for commercial sale and have not generated any revenue from the sale of products. Our ability to become and remain profitable depends on our ability to generate revenue. We do not expect to generate significant revenue, if any, unless and until we, either alone or with a collaborator, are able to obtain regulatory approval for, and successfully commercialize, our product candidate for its initial and potential additional indications, or any other